

# Efalizumab for Patients With Moderate to Severe Plaque Psoriasis

## A Randomized Controlled Trial

Kenneth B. Gordon, MD

Kim A. Papp, MD

Tiffani K. Hamilton, MD

Patricia A. Walicke, MD

Wolfgang Dummer, MD

Nicole Li, PhD

Brian W. Bresnahan, PhD

Alan Menter, MD

for the Efalizumab Study Group

**P**SORIASIS, A DISEASE AFFECTING millions of persons worldwide, is a chronic inflammatory disease that has a profound adverse effect on patients' physical, social, and mental well-being.<sup>1-6</sup> In the National Psoriasis Foundation survey of more than 17 000 respondents, 79% of patients with severe disease reported that psoriasis adversely affected their lives and limited activities of daily living (eg, work and school participation).<sup>3</sup>

The physical symptoms of psoriasis adversely affect daily functioning, with the most frequently reported symptoms including scaling, itching, and burning.<sup>3,7,8</sup> With inadequate control of these symptoms, physical, social, and mental functioning and overall health-related quality of life (HRQL) are compromised.<sup>8,9</sup> For example, the physical appearance of lesions can cause patients to experience stress and em-

**Context** Because T-cell interactions are involved in the pathophysiology of psoriasis, therapy with a T-cell modulator may have beneficial effects on psoriasis severity and health-related quality of life (HRQL).

**Objective** To assess the efficacy and safety of efalizumab, a T-cell modulator, in patients with plaque psoriasis.

**Design, Setting, and Patients** Phase 3 randomized, double-blind, parallel-group, placebo-controlled trial involving 556 adult patients with stable, moderate to severe plaque psoriasis and conducted at 30 study centers in the United States and Canada between January and July 2002.

**Interventions** Patients were randomly assigned in a 2:1 ratio to receive 12 weekly doses of subcutaneous efalizumab, 1 mg/kg (n=369), or placebo equivalent (n=187).

**Main Outcome Measures** At least 75% improvement on the Psoriasis Area and Severity Index (PASI-75); improvement on the overall Dermatology Life Quality Index (DLQI), Itching Visual Analog Scale (VAS), and Psoriasis Symptom Assessment (PSA) at week 12 vs baseline.

**Results** Efalizumab-treated patients experienced significantly greater improvement on all end points than placebo-treated patients. Twenty-seven percent of efalizumab-treated patients achieved PASI-75 vs 4% of the placebo group ( $P<.001$ ). Efalizumab-treated patients exhibited significantly greater mean percentage improvement than placebo-treated patients on the overall DLQI (47% vs 14%;  $P<.001$ ), Itching VAS (38% vs -0.2%;  $P<.001$ ), and PSA frequency and severity subscales (48% vs 18% and 47% vs 17%, respectively;  $P<.001$  for both) at the first assessment point. Efalizumab was safe and well tolerated, with primarily mild to moderate adverse events.

**Conclusion** In this 12-week study, efalizumab resulted in significant improvements in clinical end points, including physician-assessed and dermatology-specific patient-reported HRQL measures, in patients with moderate to severe plaque psoriasis.

JAMA. 2003;290:3073-3080

www.jama.com

barrassment<sup>6,10</sup> and have adverse effects on emotional aspects and normal functioning.<sup>11</sup> Up to 10% of psoriasis patients, especially younger patients, harbor suicidal thoughts compared with approximately 3% of general medical patients, indicating a significant unmet medical need.<sup>3,12</sup>

Efalizumab is a humanized monoclonal IgG1 antibody that targets T-cell interactions central to the patho-

**Author Affiliations:** Loyola University Medical Center, Maywood, Ill (Dr Gordon); Probitry Medical Research, Waterloo, Ontario (Dr Papp); Atlanta Dermatology, Vein and Research Center LLC, Atlanta, Ga (Dr Hamilton); Genentech Inc, South San Francisco, Calif (Drs Walicke, Dummer, Li, and Bresnahan); and Baylor University Medical Center, Dallas, Tex (Dr Menter). **Members of the Efalizumab Study Group** are listed at the end of this article.

**Financial Disclosures:** Dr Gordon has received research funding from Genentech Inc and Dr Papp has served as a consultant to Genentech Inc.


**Corresponding Author and Reprints:** Kenneth B. Gordon, MD, Loyola University Medical Center, 2160 S First Ave, Bldg 112, Room 342, Maywood, IL 60153 (e-mail: kgordon@lumc.edu).

See also p 3133 and Patient Page.

physiology of psoriasis.<sup>13-23</sup> In this study, the effect of efalizumab on dermatology-related HRQL in patients with moder-

ate to severe plaque psoriasis was examined using a broad set of outcome measures including physicians' assessments and patients' perceptions.

**Figure 1.** Flow of Study Participants



## METHODS

### Protocol

This phase 3 randomized, double-blind, parallel-group, placebo-controlled multicenter trial evaluated the efficacy and safety of efalizumab (anti-CD11a; Raptiva, Genentech Inc) in adults with moderate to severe psoriasis. Eligible patients were 18 to 75 years of age, diagnosed as having plaque psoriasis for at least 6 months with at least 10% of total body surface area (BSA) affected, had a minimum Psoriasis Area and Severity Index (PASI) score of 12.0 at screening, and were candidates for systemic therapy. Patients could withdraw or be withdrawn from the study at any time. All sites received institutional review board approval prior to ini-

tiating the study, and all patients provided written informed consent.

Patients were randomly assigned to receive 12 weekly doses of either subcutaneous efalizumab, 1 mg/kg, or placebo equivalent, as per the original study protocol (FIGURE 1). Allocation sequences were generated by an unblinded statistician at Genentech Inc, the study sponsor, who then passed them to the interactive voice response system vendor. The sites enrolled and randomized patients by calling the interactive voice response system, which assigned patients to either efalizumab or placebo using a random permuted-block design to obtain approximately a 2:1 ratio within categories defined by the stratification variables: baseline PASI score ( $\leq 16.0$  vs  $\geq 16.1$ ), prior treatment for psoriasis (yes vs no), and study center.

Each patient received an initial conditioning dose of 0.7 mg/kg followed by 11 weekly doses of 1 mg/kg of study drug (efalizumab or placebo equivalent). After 12 weeks of placebo-controlled treatment, all patients were enrolled in a separate long-term open-label extension study.

Patients received efalizumab monotherapy, with all phototherapy and systemic therapy excluded. Patients were permitted to use emollients. Tar and salicylic acid preparations were permitted for the scalp, and low-potency topical corticosteroids were allowed for the face, hands, feet, groin, and axillae. Patients, investigators, sponsor, and the contract research organization were blinded regarding treatment assignment or active study drug until the analyses of all data were complete.

### Assessments

The primary efficacy outcome measure was the proportion of patients with at least 75% improvement in PASI (PASI-75) at week 12 relative to baseline (BOX). The PASI is a physician-assessed score, recognized by the US Food and Drug Administration<sup>24</sup> to assess efficacy of psoriasis therapies in clinical trials, that takes into account the extent of involved skin surface area and severity of erythema, desquama-

### Box. Efficacy Outcomes Assessed During the Study

#### Physician-Assessed Outcomes

**Psoriasis Area and Severity Index (PASI):** Assesses the extent of psoriasis on 4 body surface areas (head, trunk, and upper and lower limbs) and the degree of plaque erythema, scaling, and thickness. The PASI scores account for both the extent of body surface area affected by the erythema, scaling, and thickness and the severity of these measures. The score ranges from 0 (no disease) to 72 (maximal disease).

**Overall Lesion Severity Scale (OLS):** Static global assessment with 6 categories (clear, minimal, mild, moderate, severe, and very severe) based on the characteristics of plaque elevation, scaling, and erythema.

**Physician's Global Assessment (PGA):** Captures and categorizes the global response to therapy of all clinical signs and symptoms of disease relative to baseline. Physicians use all available information for the assessment, including subjective information gathered from the patient and photographs taken at baseline. The categories are worse, unchanged, slight, fair, good, excellent, and cleared.

#### Patient-Reported Outcomes

**Dermatology Life Quality Index (DLQI):** The DLQI is a 10-item questionnaire that incorporates patients' assessments of itch, pain, feelings of embarrassment and self-consciousness, problems with their psoriasis treatment, and interference of their psoriasis with daily activities, relationships, and sexual activity. The DLQI scores range from 0 (no impairment) to 30 (maximal impairment).

**Itching Visual Analog Scale (VAS):** The 10-point Itching VAS is a modified VAS with scores ranging from 0 (no itching) to 10 (severe itching).

**Psoriasis Symptom Assessment (PSA):** The PSA is a 16-item measure of 8 psoriasis-related cutaneous symptoms (hurt, burning or stinging, itched, bothered by water, irritated, sensitive, skin condition bled, scaling). The PSA contains 2 subscales, one measuring the frequency of the 8 symptoms and the other assessing how troublesome or bothersome psoriasis symptoms are.

tion, and plaque induration.<sup>25</sup> The composite score ranges from 0 to 72, with higher numbers indicating more severe disease and a reduction in score representing improvement. The PASI components of lesion thickness, erythema, and scaling were examined separately. The PASI-75 is the currently recognized benchmark of end points used in psoriasis clinical trials.<sup>26</sup> For each study site, PASI assessments were performed by a single investigator who was blinded to randomization.

Secondary efficacy measures included 2 global physician assessments: a static measure designated the Overall Lesion Severity Scale (OLS) and a dynamic measure designated the Physician's Global Assessment (PGA). Additional secondary outcome measures were the proportion of patients with at least 50% improvement on the PASI (PASI-50) relative to baseline, the percentage of PASI improvement over time, PASI thickness component, and the percentage of BSA affected by psoriasis.

Patient-reported outcomes were evaluated using prospectively defined mean improvement in the overall Dermatology Life Quality Index (DLQI), Itching Visual Analog Scale (VAS), and Psoriasis Symptom Assessment (PSA) frequency and severity subscales. The overall improvement for all patient-reported outcomes was assessed at week 12 relative to baseline.

The DLQI measures the impact of skin disorders and treatment on patient functioning and well-being using a 7-day recall period.<sup>27</sup> The psychometric characteristics relating to the validity and reliability of the DLQI are well established.<sup>27,28</sup> The Itching VAS used in previous trials of efalizumab has been shown to be a valid and reliable measure.<sup>28</sup> The PSA is an adaptation of a validated skin disorder instrument, the Skindex,<sup>29,30</sup> with 2 additional questions related to the frequency and severity of skin scaling using a 2-week recall period. The PSA, also used in prior efalizumab studies, has been established to be a valid, reliable, and responsive measure.<sup>28</sup>

Baseline measurements were those made closest but prior to administra-

tion of the first dose of study drug. The PASI was assessed at baseline and every 2 weeks thereafter. The patient-reported outcomes (DLQI, Itching VAS, and PSA) were performed prior to obtaining physician assessments for measures (eg, PASI) at baseline and at weeks 4, 8, and 12.

The safety and tolerability of efalizumab were monitored by adverse events, vital signs, physical examination, clinical laboratory evaluation, and serum human antihuman antibody measurement. Adverse events were assessed weekly. Standard methods to assess safety were used.

### Statistical Analyses

The sample size was based primarily on safety considerations. With a planned sample size of 333 patients in the efalizumab group and 167 patients in the placebo group, using a 2-sided Fisher exact test, the study had 99% power to detect a difference between the assumed placebo response rate of 5% and the assumed efalizumab response rate of 25% at an  $\alpha = .05$  significance level. Analyses were conducted with nQuery Advisor software, version 4.0 (Statistical Solutions, Saugus, Mass).

The main analysis population for primary and secondary end points was the intention-to-treat population, consisting of all patients who were randomized whether or not they received any study drug or completed the full course of treatment. Patients were analyzed according to their randomized treatment group. Safety analyses were performed on an as-treated population.

The primary end point was evaluated by comparing the proportion of those in the efalizumab group and those in the placebo group who achieved PASI-75 at week 12 relative to baseline using a 2-sided Fisher exact test for binomial outcome at the .05 level of significance; the exact 95% confidence interval for response rates within each treatment group and the difference in response rates between the efalizumab and placebo group were calculated. Patients who discontinued early from the study or whose week 12 PASI

**Table 1.** Baseline Characteristics of Study Participants\*


Characteristics	Placebo (n = 187)	Efalizumab (n = 369)
Sex, No. (%)		
Male	132 (71)	251 (68)
Female	55 (29)	118 (32)
Race/ethnicity, No. (%)		
White	167 (89)	331 (90)
Hispanic	7 (4)	17 (5)
Other†	13 (7)	21 (6)
Age, y	45 (20-75)	45 (18-75)
Duration of psoriasis, y	19 (1-53)	19 (1-62)
Prior systemic psoriasis therapy, No. (%)		
Yes	139 (74)	283 (77)
No	48 (26)	86 (23)
PASI score	19 (11-50)	19 (10-59)
BSA affected by psoriasis, %	27 (10-90)	28 (10-95)
DLQI score	12 (0-30)	12 (0-30)
Itching VAS score	6 (0-10)	6 (0-10)
PSA frequency score	14 (2-24)	14 (2-24)
PSA severity score	15 (2-24)	15 (0-24)

Abbreviations: BSA, body surface area; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; PSA, Psoriasis Symptom Assessment; VAS, Visual Analog Scale.

\*Data are presented as mean (range) unless otherwise noted. Mean values have been rounded.

†Other includes persons who described their race/ethnicity as Asian or Pacific Islander, black, American Indian or Alaskan Native, or other.

**Figure 2.** Mean PASI Percentage Change Relative to Baseline Over the Study Period



PASI indicates Psoriasis Area and Severity Index. Error bars indicate SEMs. Asterisks indicate  $P < .001$  for efalizumab vs placebo.

score was missing were classified as nonresponders.

The following secondary end points were compared between treatment groups using a 2-sided Fisher exact test

for binomial outcome performed at the .05 level of significance: the proportion of patients who achieved an OLS rating of minimal or clear at week 12, the proportion of patients with PASI-50 at week 12 relative to day 0, and the proportion of patients who achieved a PGA rating of excellent or cleared at week

12. Using the 2-sided *t* test at the .05 significance level, mean improvement from baseline in the PASI thickness score at week 12 and mean improvement from baseline in the percentage of BSA affected by psoriasis at week 12 were compared. The PASI score and percentage of PASI improvement from

baseline were summarized by time point. At each point, the mean percentage improvement from baseline was compared between the treatment groups using the *t* test. A hierarchical testing procedure determined the earliest point at which a statistically significant difference (at the .05 level) be-

**Table 2.** Improvement From Baseline in DLQI and PSA Severity Components\*

	Baseline			Week 12		Improvement	
	No.	Mean (SD)	Median (IQR)	Mean (SD)	Median (IQR)	Mean (SD)	Median (IQR)
<b>DLQI Components</b>							
Symptoms and feelings							
Placebo	175	3.8 (1.6)	4 (3 to 5)	3.1 (1.6)	3 (2 to 4)	0.7 (1.6)	1 (0 to 2)
Efalizumab	346	4.0 (1.5)	4 (3 to 5)	2.0 (1.6)	2 (1 to 3)	1.9 (1.9)	2 (1 to 3)
Daily activities							
Placebo	172	2.5 (1.7)	2.5 (1 to 4)	2.2 (1.7)	2 (1 to 3)	0.3 (1.6)	0 (-1 to 1)
Efalizumab	347	2.5 (1.6)	2 (1 to 4)	1.4 (1.6)	1 (0 to 2)	1.1 (1.8)	1 (0 to 2)
Leisure							
Placebo	174	1.8 (1.8)	1 (0 to 3)	1.5 (1.6)	1 (0 to 2)	0.3 (1.6)	0 (0 to 1)
Efalizumab	345	1.8 (1.8)	1 (0 to 3)	0.8 (1.3)	0 (0 to 1)	1.0 (1.7)	0 (0 to 2)
Work and school							
Placebo	171	0.7 (0.9)	0 (0 to 1)	0.5 (0.8)	0 (0 to 1)	0.2 (0.8)	0 (0 to 0)
Efalizumab	335	0.8 (0.9)	1 (0 to 1)	0.3 (0.7)	0 (0 to 1)	0.4 (0.9)	0 (0 to 1)
Personal relationships							
Placebo	175	1.5 (1.7)	1 (0 to 2)	1.2 (1.6)	1 (0 to 2)	0.3 (1.3)	0 (0 to 1)
Efalizumab	346	1.4 (1.7)	1 (0 to 2)	0.7 (1.3)	0 (0 to 1)	0.7 (1.6)	0 (0 to 2)
Treatment							
Placebo	175	1.2 (1.1)	1 (0 to 2)	1.3 (1.0)	1 (1 to 2)	0 (1.0)	0 (-1 to 0)
Efalizumab	346	1.3 (1.0)	1 (0 to 2)	0.7 (0.8)	1 (0 to 1)	0.6 (1.1)	1 (0 to 1)
<b>PSA Severity Subscales†</b>							
Hurt							
Placebo	176	1.8 (1.0)	2 (1 to 3)	1.4 (1.0)	1 (1 to 2)	0.4 (1.0)	0 (0 to 1)
Efalizumab	343	1.8 (1.0)	2 (1 to 3)	0.8 (0.9)	1 (0 to 1)	0.9 (1.2)	1 (0 to 2)
Burning or stinging							
Placebo	176	1.7 (1.0)	2 (1 to 2)	1.4 (1.0)	1 (1 to 2)	0.3 (1.0)	0 (0 to 1)
Efalizumab	343	1.7 (1.0)	2 (1 to 3)	0.8 (0.9)	1 (0 to 1)	0.9 (1.2)	1 (0 to 2)
Itched							
Placebo	175	2.4 (0.8)	3 (2 to 3)	2.1 (0.9)	2 (1 to 3)	0.3 (0.8)	0 (0 to 1)
Efalizumab	338	2.4 (0.8)	3 (2 to 3)	1.3 (0.9)	1 (1 to 2)	1.1 (1.0)	1 (0 to 2)
Bothered by water							
Placebo	176	1.1 (1.1)	1 (0 to 2)	0.9 (1.0)	1 (0 to 2)	0.2 (1.0)	0 (0 to 1)
Efalizumab	342	1.1 (1.1)	1 (0 to 2)	0.6 (0.9)	0 (0 to 1)	0.5 (1.1)	0 (0 to 1)
Irritated							
Placebo	175	2.1 (0.9)	2 (2 to 3)	1.6 (0.9)	2 (1 to 2)	0.5 (0.9)	0 (0 to 1)
Efalizumab	343	2.0 (0.9)	2 (1 to 3)	1.0 (0.9)	1 (0 to 2)	1.0 (1.1)	1 (0 to 2)
Sensitive							
Placebo	175	1.9 (0.9)	2 (1 to 3)	1.6 (1.0)	1 (1 to 2)	0.3 (1.0)	0 (0 to 1)
Efalizumab	343	1.9 (1.0)	2 (1 to 3)	1.0 (1.0)	1 (0 to 1)	0.9 (1.1)	1 (0 to 2)
Skin condition bled							
Placebo	175	1.3 (0.9)	1 (1 to 2)	1.2 (0.9)	1 (0 to 2)	0.1 (0.9)	0 (0 to 1)
Efalizumab	343	1.3 (0.9)	1 (1 to 2)	0.6 (0.8)	0 (0 to 1)	0.7 (1.0)	1 (0 to 1)
Scaling							
Placebo	176	2.6 (0.6)	3 (2 to 3)	2.1 (0.9)	2 (1 to 3)	0.5 (0.9)	0 (0 to 1)
Efalizumab	344	2.5 (0.8)	3 (2 to 3)	1.2 (1.0)	1 (1 to 2)	1.3 (1.1)	1 (0 to 2)

Abbreviations: DLQI, Dermatology Life Quality Index; IQR, interquartile range; PSA, Psoriasis Symptom Assessment.

\**P* values calculated by 2-sample Wilcoxon rank sum test for between-group comparisons of improvement were <.001 for all comparisons.

†For this measure patients were asked to indicate how troubling/bothersome each listed symptom was during the previous 2 weeks.

tween the treatment groups was observed. No multiple-comparison adjustment for the type I error was made in the hierarchical testing procedure, since there was no inflation of the type I error. To ensure an overall type I error rate of  $\alpha = .05$  (2-sided) for all secondary efficacy analyses, the Hochberg-Bonferroni<sup>31</sup> multiple-comparisons procedure was used to adjust for multiple comparisons of secondary end points; all secondary end points retained statistical significance after multiplicity adjustments.

Mean improvements from baseline to week 12 on the overall DLQI and each of the 2 PSA scales were compared between treatment groups using the Wilcoxon rank sum test. The mean improvement from baseline in the Itching VAS at week 12 was compared between treatment groups using the *t* test. The overall scores and improvements from baseline for all patient-reported outcome scales were summarized by time point. At each point, the mean percentage improvement from baseline was compared between the treatment groups using the Wilcoxon rank sum test (DLQI and PSA) or *t* test (Itching VAS). A hierarchical testing procedure was used, as for efficacy.

## RESULTS

### Patient Characteristics

Between January and July 2002, 556 patients were enrolled at 30 study centers and randomized into the study, 369 patients into the 1-mg/kg-per-week efalizumab group and 187 patients into the placebo group (Figure 1). There were no statistically significant differences between the 2 treatment groups with respect to demographics, baseline characteristics, and disease severity (TABLE 1). The mean PASI score at baseline for the entire study cohort was 19, and mean BSA with psoriasis was 28% for the efalizumab-treated group and 27% for the placebo-treated group. The proportion of patients who did not complete treatment was similar in both groups (6.5% vs 6.4%); the most common reasons were patient decision (n=10), loss to follow-up (n=9), ad-

**Table 3.** DLQI Improvement Stratified by PASI Response at Week 12

	PASI Improvement, %		
	≥75	51-74	≤50
<b>Placebo</b>			
No. (%) of patients	8 (4)	18 (10)	157 (86)
Mean (SD) improvement	8.8 (5.5)	6.8 (5.7)	2.5 (6.5)
Median (IQR) improvement	8 (5 to 12)	5 (2 to 11)	2 (-1 to 6)
<b>Efalizumab</b>			
No. (%) of patients	98 (27)	118 (32)	153 (41)
Mean (SD) improvement	8.8 (5.5)	6.8 (5.7)	2.5 (6.5)
Median (IQR) improvement	8 (5 to 12)	5 (2 to 11)	2 (-1 to 6)

Abbreviations: DLQI, Dermatology Life Quality Index; IQR, interquartile range; PASI, Psoriasis Area and Severity Index.

verse event (n=9), use of an excluded medication (n=5), and investigator decision (n=3) (Figure 1). Four hundred seventeen patients (75%) received all 12 doses of assigned study drug.


### Treatment Efficacy

**Physician-Assessed Outcomes.** At the end of the 12-week treatment course, 27% of patients treated with efalizumab (98/369) achieved PASI-75 compared with 4% of patients who received placebo (8/187;  $P < .001$ ). The treatment effect, defined as the difference in the proportion of patients who achieved PASI-75 between the efalizumab and placebo groups, was 22.3% (95% confidence interval, 15.8%-29.5%). Fifty-nine percent of efalizumab-treated patients (216/369) achieved PASI-50 compared with 14% of patients receiving placebo (26/187;  $P < .001$ ). The mean PASI improvement at week 12 in the efalizumab-treated patients relative to baseline was about 52% compared with 19% in the patients who received placebo ( $P < .001$ ) (FIGURE 2).

The proportion of patients with an OLS rating of minimal or clear at week 12 in the efalizumab group was significantly higher than that in the placebo group (26% vs 3%;  $P < .001$ ). Similarly, the proportion of patients with a PGA rating of excellent or cleared at week 12 was significantly greater in the efalizumab group compared with the placebo group (33% vs 5%;  $P < .001$ ).

**Patient-Reported Outcomes.** At week 12, the mean percentage improvement from baseline in DLQI overall score was

**Figure 3.** Median Change in PSA Severity Relative to Baseline Over the Study Period



PSA indicates Psoriasis Symptom Assessment. Error bars indicate interquartile ranges.

greater in the efalizumab-treated group than in the placebo group (47% vs 14%;  $P < .001$ ). Patients in the efalizumab-treated group showed improvement in mean DLQI scores compared with the placebo-treated group at 28 days ( $P < .001$ ). Given the 1-week recall period associated with the DLQI, this difference in score between the 2 groups indicates that reduced dermatology-related limitations and improved functioning occurred fairly soon after initiating efalizumab therapy. There was a statistically significant trend toward a positive efalizumab treatment effect across all DLQI components (TABLE 2), with the greatest difference between the treatment groups at week 12 observed in the "symptoms and feelings" domain (48% vs 18%). Additional analy-

**Table 4.** Adverse Events Occurring in at Least 5% of All Patients

Adverse Events	No. (%) of Patients		P Value†
	Placebo (n = 187)	Efalizumab (n = 368)*	
Total‡	133 (71)	296 (80)	.02
Headache	39 (21)	123 (33)	.002
Infection, not otherwise specified	23 (12)	46 (13)	>.99
Chills	10 (5)	44 (12)	.01
Nausea	13 (7)	39 (11)	.22
Myalgia	8 (4)	38 (10)	.01
Pain	9 (5)	37 (10)	.03
Pharyngitis	10 (5)	27 (7)	.47
Flulike syndrome	7 (4)	27 (7)	.13
Fever	3 (2)	25 (7)	.007
Rhinitis	11 (6)	23 (6)	>.99
Asthenia	9 (5)	22 (6)	.70
Diarrhea	10 (5)	20 (5)	>.99
Unintentional injury	19 (10)	17 (5)	.02

\*Excludes 1 patient who was randomized but discontinued before receiving any study drug.

†P values were calculated using a 2-sided Fisher exact test for binomial distributions.

‡Patients with at least 1 adverse event.

ses showed the summary statistics on DLQI improvement stratified by PASI response at week 12 in the 369 patients who were randomized to receive efalizumab, with the greatest improvement observed in the patients who achieved PASI-50 (TABLE 3).

When patients with a baseline Itching VAS score of 0 (9 patients in the efalizumab group and 3 in the placebo group) were excluded from the analysis, efalizumab treatment was shown to produce a 38% improvement in Itching VAS score, compared with a slight worsening in score (−0.2%) in the placebo group at 12 weeks ( $P < .001$ ). A significant improvement in the mean Itching VAS in the efalizumab group relative to the placebo group was observed at the first time point measured ( $P < .001$ ).

Comparisons of the mean percentage improvement from baseline in the efalizumab group vs the placebo group were statistically significant for both frequency of symptoms (48% vs 18%;  $P < .001$ ) and severity of symptoms (eg, troubling or bothersome) (47% vs 17%;  $P < .001$ ). Improvement in both mean PSA frequency and mean PSA severity subscale scores was evident in the efalizumab group vs the placebo group at the first time point at which PSA was measured ( $P < .001$ ) (FIGURE 3). There

was a trend toward improvement across all symptoms in both frequency and severity in the efalizumab group, as evidenced by the mean improvement in PSA scores (Table 2). With respect to the frequency of symptoms, differences between absolute improvements were similar for most symptoms (itching, irritation, sensitivity, bleeding, and scaling). With respect to severity, or how bothersome the symptoms were, the largest absolute improvements occurred in both the itching (mean improvement of 1.1 for efalizumab vs 0.3 for placebo;  $P < .001$ ) and scaling (1.2 for efalizumab vs 0.4 for placebo;  $P < .001$ ) components.

### Safety Evaluation

Efalizumab therapy was generally well tolerated. All adverse events that occurred in at least 5% of all patients are shown in TABLE 4. Five types of adverse events (headache, chills, fever, myalgia, and pain) occurred at least 5% more frequently in the efalizumab group than in the placebo group. These events tended to be a portion of the complex of mild to moderate flulike symptoms that occur following the first 1 to 2 injections of efalizumab.

Serious adverse events were infrequent, occurring in 2% of efalizumab-

treated patients (9/368) and 1% of placebo-treated patients (1/187). No deaths were reported for patients during the study. Fourteen patients (3%) (12 [3%] in the efalizumab group and 2 [1%] in the placebo group) experienced adverse events that resulted in withdrawal of study drug.

No clinically significant laboratory abnormalities or pattern of changes in vital signs were observed during efalizumab treatment. Eight patients (2%) developed positive antibodies to efalizumab after exposure to the drug. None of these patients experienced serious adverse events or discontinued treatment. No patients in the placebo group developed anti-efalizumab antibodies.

The rate of diagnosed infections was 27% for the efalizumab group and 23% for the placebo group. Infections that occurred at least 1% more frequently in the efalizumab-treated patients than in the placebo-treated patients included mild to moderate viral infection (primarily mild to moderate viral upper respiratory tract infections), bacterial infection (eg, impetigo, streptococcal pharyngitis), cellulitis, and fungal (yeast) infection. Infections graded as severe occurred in 0.5% of patients in both the efalizumab and placebo groups. Efalizumab-treated patients did not exhibit increased susceptibility to any one type of pathogen, nor was there evidence of infection characteristic of opportunistic infections observed in immunocompromised hosts.

No cases of anaphylaxis were observed during efalizumab therapy. During the study, 2 cases of malignancy were diagnosed (1 case each of squamous cell cancer at day 2 and basal cell cancer at day 77) in efalizumab-treated patients, although neither was judged as being related to efalizumab by investigators.

### COMMENT

Limitations of currently available psoriasis therapies highlight the need for effective and safe treatment options. Traditional systemic therapies are associated with cumulative toxic effects, potentially increasing the risk of end-organ

damage or malignancy.<sup>32,33</sup> In this phase 3 randomized, placebo-controlled trial, efalizumab therapy resulted in significant improvement in the primary end point and other prespecified efficacy end points. The efficacy, accompanied by the safety profile and the HRQL outcomes, provides evidence of potential benefit for efalizumab in patients with psoriasis. By week 12, 27% of efalizumab-treated patients achieved a PASI-75 response compared with 4% of placebo-treated patients. These results are consistent with the physician-reported outcomes from another recently reported trial of efalizumab.<sup>34</sup> Efalizumab-treated patients demonstrated significant benefit on the additional physician-assessed global psoriasis scales, OLS and PGA, compared with placebo-treated patients. Consistent and significant improvements on multiple dermatology- and psoriasis-specific patient-reported end points were observed throughout the study.

The magnitude of the percentage improvement in HRQL was greater than that for PASI in the early stage of treatment. Improvement in the individual PASI components occurred early; however, it is likely that the BSA component, which improves less rapidly, underestimates the improvement occurring in the lesions. This suggests that concentrating solely on PASI improvement might underestimate the timing and overall response to efalizumab.

Efalizumab treatment reduced the frequency and severity of psoriasis symptoms, particularly in the severity of itching and scaling, the 2 most frequently reported subjective symptoms.<sup>3</sup> The severity and frequency of other symptoms, including bleeding and burning or stinging, also were improved by efalizumab treatment. The significant improvement on the DLQI indicated consistent improvements across measures of social and mental assessment (Table 2), areas known to be adversely affected in patients with psoriasis. Efalizumab-treated patients reported greater improvement in their attitudes about their disease, their ability to participate in daily activities (includ-

ing leisure and work), and their personal relationships, and they reported fewer treatment-related problems compared with placebo.

Efalizumab exhibited a favorable safety profile and was generally well tolerated. The most commonly occurring adverse events during the initiation of efalizumab treatment were mild to moderate flulike symptoms following the first 1 to 2 injections. Serious adverse events were infrequent and occurred at only a slightly greater frequency in the efalizumab group (2%) than in the placebo group (1%). There was no evidence to suggest clinically relevant increases in either infection or malignancy, including lymphoma, among efalizumab-treated patients; however, longer follow-up will be needed to accurately characterize the risk of infection and malignancy.

There were no clinically relevant laboratory abnormalities. Previous efalizumab studies in psoriasis patients have shown that the discrete elevations in lymphocyte counts, white blood cell counts, and other hematologic parameters are transient, usually within normal ranges, with values returning to baseline following efalizumab discontinuation.<sup>35-37</sup> There was no evidence of general systemic toxicity reflected by changes in hepatic or renal function.

This investigation is limited by the relatively short duration and by lack of an active comparator. Since psoriasis is a chronic disease, outcomes with longer-term use of efalizumab are important. The efficacy and safety of longer-term efalizumab treatment has been further evaluated in an extension of this study that analyzes up to 24 weeks of continuous efalizumab therapy. The preliminary analysis of data from this study suggests continued improvement in disease severity and maintenance of safety. Additionally, an ongoing open-label study evaluating the efficacy and safety of up to 3 years of continuous efalizumab therapy is currently being conducted. Efficacy with continued use of efalizumab has also been suggested in a recently reported clinical trial.<sup>34</sup> The current study

did not compare efalizumab directly with any of the currently used therapies for psoriasis. Additional randomized studies would be needed to compare this profile with other currently available therapies.

Efalizumab was recently approved for treatment of patients with chronic moderate to severe plaque psoriasis.<sup>38</sup> The benefit across physician-assessed end points and multiple patient-reported measures of HRQL observed in this study along with the favorable safety profile suggest that efalizumab could provide a viable treatment option for patients with moderate to severe plaque psoriasis.

**Author Contributions:** Dr Gordon had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Gordon, Papp, Walicke, Dummer, Bresnahan.

**Acquisition of data:** Gordon, Papp, Hamilton, Dummer. **Analysis and interpretation of data:** Gordon, Papp, Walicke, Dummer, Li, Bresnahan, Menter.

**Drafting of the manuscript:** Gordon, Dummer, Li, Bresnahan.

**Critical revision of the manuscript for important intellectual content:** Gordon, Papp, Hamilton, Walicke, Dummer, Li, Bresnahan, Menter.

**Statistical expertise:** Gordon, Li.

**Obtained funding:** Papp.

**Administrative, technical, or material support:** Gordon, Papp, Hamilton, Walicke, Bresnahan.

**Study supervision:** Gordon, Walicke, Dummer, Menter.

**The Efalizumab Study Group:** Jerry Bagel, MD, Radiant Research, Lawrenceville, NJ; Karl R. Beutner, MD, Solano Clinical Research, Davis, Calif; Wayne Carey, MD, Royal Victoria Hospital, Montreal, Quebec; Frank E. Dunlap, MD, Radiant Research, Tucson, Ariz; Steven R. Feldman, MD, Wake Forest University, Winston-Salem, NC; Gunnar Gibson, BGPDS Dermatology, Little Rock, Ark; Scott Glazer, MD, Buffalo Grove, Ill; Mitchell Goldman, MD, Dermatology Associates of San Diego, Encinitas, Calif; J. John Goodman, MD, Radiant Research, West Palm Beach, Fla; Kenneth B. Gordon, MD, Loyola University, Maywood, Ill; Wayne P. Gulliver, MD, Newlab Clinical Research Inc, St John's, Newfoundland; Tiffani K. Hamilton, MD, Atlanta Dermatology, Vein, and Research Center LLC, Alpharetta, Ga; Dan C. Henderson, MD Rockwood Clinic, PS, Spokane, Wash; Paul Krusinski, MD, Fletcher Allen Health Care, UHC, Burlington, Vt; Richard Langley, MD, QE II Health Science Centre, Halifax, Nova Scotia; Charles Lynde, MD, Lynde Center for Dermatology, Markham, Ontario; Robert Matheson, MD, Oregon Medical Research Center, Portland; Mark McCune, MD, Radiant Research, Overland Park, Kan; Alan Menter, MD, Texas Dermatology Research Institute, Dallas; Kim Papp, MD, Probit Medical Research, Waterloo, Ontario; Jerold Powers, MD, Radiant Research, Scottsdale, Ariz; Elyse Rafal, MD, DermResearch Center of New York Inc, Stony Brook; Michael Scannon, MD, St Joseph Comprehensive Research Institute, Tampa, Fla; Elaine Siegfried, MD, Central Dermatology, St Louis, Mo; James M. Swineheart, MD, Colorado Medical Research Center, Denver; Naji Tawfik, MD, PhD, Welborn Clinic, Evansville, Ind; Darryl Toth, MD, Probit Medical Research, Windsor, Ontario; Stephen Ty-

ring, MD, University of Texas Medical Branch, Houston; Michael D. Zanolli, MD, Dermatology Consultants, Nashville, Tenn.

**Funding/Support:** The data presented herein are derived from a clinical trial sponsored by Genentech Inc, which provided the study drug and placebo for this trial.

**Role of the Sponsor:** Drs Walicke and Dummer, employees of Genentech Inc, the sponsor of this clinical trial, contributed to the design of this protocol and the interpretation of the results. Additionally, the database derived from the findings of the individual investigators from 30 study sites was maintained by Genentech and statistical analyses were performed at Genentech by Dr Li in conjunction with Dr Gordon, the lead author of this article. Dr Gordon was responsible for the development of the manuscript but all authors, including those employed by Genentech, reviewed and edited the manuscript.

**Acknowledgment:** We acknowledge the contribution of Kirsten M. Duncan, PharmD, to the development of the manuscript.

## REFERENCES

- Christophers E. Psoriasis—epidemiology and clinical spectrum. *Clin Exp Dermatol.* 2001;26:314-320.
- Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. *Br J Dermatol.* 1995;132:236-244.
- Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. *Arch Dermatol.* 2001;137:280-284.
- McKenna KE, Stern RS. The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. *J Am Acad Dermatol.* 1997;36:388-394.
- Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. *J Am Acad Dermatol.* 1999;41:401-407.
- Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. *J Am Acad Dermatol.* 2002;47:512-518.
- Gupta MA, Gupta AK, Kirkby S, et al. Pruritus in psoriasis: a prospective study of some psychiatric and dermatologic correlates. *Arch Dermatol.* 1988;124:1052-1057.
- Yosipovitch G, Goon A, Wee J, Chan YH, Goh CL. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. *Br J Dermatol.* 2000;143:969-973.
- Leary MR, Rapp SR, Herbst KC, Exum ML, Feldman SR. Interpersonal concerns and psychological difficulties of psoriasis patients: effects of disease severity and fear of negative evaluation. *Health Psychol.* 1998;17:530-536.
- Gupta MA, Gupta AK. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. *Acta Derm Venereol.* 1995;75:240-243.
- Wahl A, Loge JH, Wiklund I, Hanestad BR. The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. *J Am Acad Dermatol.* 2000;43(5 pt 1):803-808.
- Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. *Br J Dermatol.* 1998;139:846-850.
- Gilhar A, David M, Ullmann Y, Berkutski T, Kalish RS. T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. *J Invest Dermatol.* 1997;109:283-288.
- Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. *Nat Med.* 1995;1:442-447.
- Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. *Immunol Today.* 1999;20:40-60.
- Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. *J Am Acad Dermatol.* 2002;46:1-23.
- Springer TA, Dustin ML, Kishimoto TK, Marlin SD. The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. *Annu Rev Immunol.* 1987;5:223-252.
- Dustin ML, Springer TA. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. *J Cell Biol.* 1988;107:321-331.
- Kuyper TW, Roos D. Leukocyte membrane adhesion proteins LFA-1, CR3 and p150,95: a review of functional and regulatory aspects. *Res Immunol.* 1989;140:461-486.
- Nickoloff BJ, Griffiths CE, Barker JN. The role of adhesion molecules, chemotactic factors, and cytokines in inflammatory and neoplastic skin disease: 1990 update. *J Invest Dermatol.* 1990;94(6 suppl):151S-157S.
- Werther WA, Gonzalez TN, O'Connor SJ, et al. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. *J Immunol.* 1996;157:4986-4995.
- Dustin ML, Springer TA. Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. *Annu Rev Immunol.* 1991;9:27-66.
- Krueger J, Gottlieb A, Miller B, Dedrick R, Garovoy M, Walicke P. Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. *J Invest Dermatol.* 2000;115:333.
- Menter AM, Krueger GC, Feldman SR, Weinstein GD. Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authors. *J Am Acad Dermatol.* 2003;49(2 suppl):S39-S43.
- Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. *Br J Dermatol.* 1999;141:185-191.
- Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? what constitutes a clinically significant improvement when treating psoriasis? *J Am Acad Dermatol.* 2000;43:281-285.
- Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. *Clin Exp Dermatol.* 1994;19:210-216.
- Shikhar R, Thompson C. *Validity of Patient-Reported Outcomes Used in Psoriasis: Results From Two Randomized Clinical Trials.* Bethesda, Md: MED-TAP International Inc; December 2002:1-95.
- Chren M-M, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. *J Invest Dermatol.* 1996;107:707-713.
- Chren M-M, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. *Arch Dermatol.* 1997;133:1433-1440.
- Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. *Biometrika.* 1988;75:800-802.
- Greaves MW, Weinstein GD. Treatment of psoriasis. *N Engl J Med.* 1995;332:581-588.
- Gottlieb AB. Psoriasis. *Dis Manag Clin Outcomes.* 1998;1:195-202.
- Lebwohl M, Tyring SK, Hamilton TK, et al, for the Efalizumab Study Group. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. *N Engl J Med.* 2003;349:2004-2013.
- Gottlieb A, Krueger JG, Bright R, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. *J Am Acad Dermatol.* 2000;42:428-435.
- Papp K, Bissonnette R, Krueger JG, et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. *J Am Acad Dermatol.* 2001;45:665-674.
- Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. *Arch Dermatol.* 2002;138:591-600.
- Papadopoulos E, Marzella L, Gnecco C. Briefing document: biologic license application STN BL 125075/0 for efalizumab for the treatment of moderate to severe chronic plaque psoriasis. Rockville, Md: US Food and Drug Administration; September 2003. Available at: [http://www.fda.gov/ohrms/dockets/ac/03/briefing/3983B1\\_02\\_FDA=Raptiva.htm](http://www.fda.gov/ohrms/dockets/ac/03/briefing/3983B1_02_FDA=Raptiva.htm). Accessibility verified November 21, 2003.

rorism agents. Examining each of the 6 diseases individually, the percentage of jurisdictions that mandate reporting ranged from a low of 44% (viral hemorrhagic fevers) to a high of 100% (anthrax, botulism).

**Comment.** To our knowledge, this is the first description of the use of the Web by states and territories for reporting of infectious diseases. Our results indicate that while most jurisdictions maintain Web sites, many did not clearly describe what, when, how, and where health care providers should report diseases. We also found considerable variation in Web-based information on reporting requirements for diseases potentially related to bioterrorism. Including explicit requirements to report all Category A diseases on a jurisdiction's reportable disease list not only reduces uncertainty about what is reportable, but also raises awareness of these threats.<sup>5,6</sup>

Because most jurisdictions already maintain Web sites, updating them to provide complete, accessible disease reporting information should be relatively inexpensive. More effective use of the Web could strengthen the partnership among clinicians and local public health officials that is vital for recognition of and response to disease outbreaks and bioterrorism-related events.

Nkuchia M. M'ikanatha, DrPH, MPH  
nmikanatha@state.pa.us

Division of Infectious Disease Epidemiology  
Pennsylvania Department of Health  
Harrisburg

David P. Welliver, MS, MBA  
Penn State Milton S. Hershey Medical Center  
Hershey

Dale D. Rohn, MPH  
Maryland Department of Health and Mental Hygiene  
Baltimore

Kathleen G. Julian, MD  
Penn State Milton S. Hershey Medical Center  
Ebbing Lautenbach, MD, MPH, MSCE  
Center for Clinical Epidemiology and Biostatistics  
University of Pennsylvania School of Medicine  
Philadelphia

**Acknowledgment:** We thank Samuel Groseclose, DVM, MPH, of the US Centers for Disease Control and Prevention for his assistance with the contacts for the 4 US territories that participate in the National Notifiable Disease Surveillance System. We also thank James T. Rankin, DVM, PhD, of the Pennsylvania Department of Health for his comments on the survey instrument.

1. Chorba TL, Berkman RL, Safford SK, Gibbs NP, Hull HF. Mandatory reporting of infectious diseases by clinicians. *JAMA*. 1989;262:3018-3026.
2. Konowitz PM, Petrossian GA, Rose DN. The underreporting of disease and physicians' knowledge of reporting requirements. *Public Health Rep*. 1984;99:31-35.
3. American Medical Association. New AMA study shows physicians' use of Internet steadily rising. Available at: <http://www.ama-assn.org/ama/pub/print/article/1615-6477.html>. Accessed July 19, 2002.
4. Centers for Disease Control and Prevention. Bioterrorism Agents/Diseases. Available at: <http://www.bt.cdc.gov/agent/agentlist-category.asp>. Accessed December 30, 2003.
5. Centers for Disease Control and Prevention. National Notifiable Disease Surveillance System. Available at: <http://www.cdc.gov/epo/dphsi/nndsshis.htm>. Accessed December 29, 2003.
6. Horton HH, Misrahi JJ, Matthews GW, Kocher PL. Critical biological agents: disease reporting as a tool for determining bioterrorism preparedness. *J Law Med Ethics*. 2002;30:262-266.

## CORRECTION

**Incorrect Table:** In the Original Contribution entitled "Efaluzimab for Patients With Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial" published in the December 17, 2003, issue of THE JOURNAL (2003;290:3073-3080), Table 2 contained erroneous numbers for mean (SD) and median (IQR) placebo group improvement; additionally, erroneous PASI improvement percentage headings were shown. The correct table is shown below.

**Table 3.** DLQI Improvement Stratified by PASI Response at Week 12

	PASI Improvement, %		
	≥75	50-74	<50
<b>Placebo</b>			
No. (%) of patients (n = 183)*	8 (4)	18 (10)	157 (86)
Mean (SD) improvement	6.5 (5.4)	8.2 (7.1)	0.6 (4.9)
Median (IQR) improvement	5.5 (3 to 10.5)	6.5 (4 to 13)	1 (-2 to 3)
<b>Efaluzimab</b>			
No. (%) of patients (n = 363)*	97 (27)	117 (32)	149 (41)
Mean (SD) improvement	8.8 (5.5)	6.8 (5.7)	2.5 (6.5)
Median (IQR) improvement	8 (5 to 12)	5 (2 to 11)	2 (-1 to 6)

Abbreviations: DLQI, Dermatology Life Quality Index; IQR, interquartile range; PASI, Psoriasis Area and Severity Index.

\*Data are derived from the number of patients for whom values were available.